<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>


    <DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman">U.S.
SECURITIES AND EXCHANGE COMMISSION</FONT></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman">Washington,
D.C. 20549</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman">FORM
8-K</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman">CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)</FONT></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman">OF
THE SECURITIES EXCHANGE ACT OF 1934</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">Date of
Report (Date of earliest event reported): March 13, 2012</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
            <TR>
              <TD STYLE="vertical-align: top; width: 85%">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">NUTRA
      PHARMA CORP.</FONT></DIV>
              </TD>
            </TR>
            <TR>
              <TD STYLE="vertical-align: top; width: 85%">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">(Exact
      name of registrant as specified in its
charter)</FONT></DIV>
              </TD>
            </TR>
        </TABLE>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <DIV STYLE="text-align: center">
          <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
              <TR>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman"><U>California</U></FONT></DIV>
                </TD>
                <TD STYLE="vertical-align: top; width: 28%"><DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman"><U>000-32141</U></FONT></DIV>
                </TD>
                <TD STYLE="vertical-align: top; width: 28%"><DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman"><U>91-2021600</U></FONT></DIV>
                </TD>
              </TR>
              <TR>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman">(State
      or jurisdiction of</FONT></DIV>
                </TD>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman">(Commission</FONT></DIV>
                </TD>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman">(I.R.S.
      Employer</FONT></DIV>
                </TD>
              </TR>
              <TR>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman">incorporation
      or organization)</FONT></DIV>
                </TD>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman">File
      Number)</FONT></DIV>
                </TD>
                <TD STYLE="vertical-align: top; width: 28%">
                  <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt times new roman">Identification
      No.)</FONT></DIV>
                </TD>
              </TR>
          </TABLE>
        </DIV>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
            <TR>
              <TD STYLE="vertical-align: top; width: 85%">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">2776
      University Drive</FONT></DIV>
              </TD>
            </TR>
            <TR>
              <TD STYLE="vertical-align: top; width: 85%">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">Coral
      Springs, Florida 33065</FONT></DIV>
              </TD>
            </TR>
            <TR>
              <TD STYLE="vertical-align: top; width: 85%">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">(Address
      of principal executive offices) (Zip
Code)</FONT></DIV>
              </TD>
            </TR>
        </TABLE>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
            <TR>
              <TD STYLE="vertical-align: top; width: 85%">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">Registrant's
      telephone number: 954-509-0911</FONT></DIV>
              </TD>
            </TR>
        </TABLE>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
            <TR>
              <TD STYLE="text-align: left; vertical-align: top; width: 85%"><FONT STYLE="font: 10pt Times New Roman">&#160;
      </FONT></TD>
            </TR>
        </TABLE>
      </DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman">(Former
name or former address, if changed since last report)</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left">&#160;</DIV>
      <DIV ID="PGBRK" STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">
        <DIV ID="FTR">
          <DIV ID="GLFTR" STYLE="width: 100%; text-align: left">&#160;</DIV>
        </DIV>
        <DIV ID="PN" STYLE="page-break-after: always">
          <DIV STYLE="width: 100%; text-align: center">&#160;</DIV>
          <DIV STYLE="width: 100%; text-align: center">
            <HR NOSHADE SIZE="2" STYLE="color: black">
          </DIV>
        </DIV>
        <DIV ID="HDR">
          <DIV ID="GLHDR" STYLE="width: 100%; text-align: right">&#160;</DIV>
        </DIV>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: bold 10pt Times New Roman">Nutra
Pharma Corp. is referred to herein as &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&rdquo; or the &ldquo;Company&rdquo;.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: bold 10pt Times New Roman">Item
1.01&#160;&#160;&#160;&#160;Entry into a Material Definitive
Agreement.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV></DIV>

<P STYLE="color: rgb(79,129,189); font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">On March 13,
2012, we signed a $10,000,000 maximum commitment amount Equity Purchase Agreement (the &ldquo;Agreement&rdquo;) with Southridge
Partners, II. LP (&ldquo;SPLP&rdquo;), a Delaware Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Agreement provides that we will sell to SPLP
(referred to in the Agreement as the &ldquo;Investor&rdquo;) and SPLP will purchase up to ten million dollars
($10,000,000) of our common stock under specified terms in the Agreement. The Agreement provides that on any Put Date, we may
exercise a Put by the delivery of a Put Notice to SPLP. The number of Put Shares that SPLP will purchase will be determined
by dividing the investment amount specified in the Put Notice by the Purchase Price. The Investment amount identified in the
Put Notice will not be greater than the Maximum Put Amount, and, when taken together with any prior Put Notices, will not
exceed the Maximum Commitment of $10,000,000. On the Put Date, we will deliver to SPLP&rsquo;s brokerage account estimated
put shares equal to the investment amount indicated in the Put Notice divided by the closing price on the trading day
immediately proceeding the Put Date, multiplied by one hundred twenty five percent (125%). On the Trading Date immediately
following delivery of the Estimated Put Shares, SPLP will delivery payment by check or wire transfer to us an amount equal to
the part value of the Estimated Put Shares. In the event that, during a Valuation Period, the Closing Price on any Trading
Day falls more than twenty percent (20%) below the average of closing trade prices for the five (5) trading days immediately
preceding the date of our Put Notice, for each such Trading Day, the parties shall have no right and will be under no
obligation to purchase and sell one fifth (1/5) of the investment amount specified in the Put Notice, and the Investment
Amount will accordingly be deemed reduced by such amount. The Put Shares are contingent upon our filing of an S-1
Registration Statement with the Securities Exchange Commission and it becoming effective.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a condition of executing the Agreement by SPLP, we
will issue to SPLP a promissory note in the amount of $50,000 upon the signing of the Agreement. The Note will be convertible
at SPLP&rsquo;s option into shares of our common stock at a conversion price equal to seventy percent (70%) of the average of
the two (2) lowest Closing Prices for the five (5) trading days immediately preceding a conversion notice. Additionally, we
agree to pay our own expenses in connection with preparation of the Agreement and performance of our obligations under the
Agreement, and we will pay a $25,000 fee to SPLP in cash or the issuance of an additional $25,000 in principal of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Agreement is subject to various representations and warranties
by both parties to the Agreement.</P>



<DIV><DIV STYLE="text-indent: 0pt"></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: bold 10pt Times New Roman">Item
3.02&#160;&#160;&#160;&#160;Unregistered Sales of Equity
Securities.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman">The
information contained above in Item&#160;1.01 is hereby incorporated by
reference into this Item 3.02.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: bold 10pt Times New Roman">Item
9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman">(d)
Exhibits.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" ID="hangingindent" STYLE="width: 100%">
            <TR STYLE="vertical-align: top">
              <TD STYLE="width: 36pt">
                <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt"><FONT STYLE="font: 10pt Times New Roman">10.1</FONT></DIV>
              </TD>
              <TD>
                <DIV STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman">
      Equity Agreement, dated as of March 13, 2012, by and between the Company and
      Southridge Partners II, LP.</FONT></DIV>
              </TD>
            </TR>
        </TABLE>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV>
        <TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" ID="hangingindent" STYLE="width: 100%">
        </TABLE>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left">
        <TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" ID="hangingindent" STYLE="width: 100%">
        </TABLE>
      </DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center"><FONT STYLE="font: bold 10pt Times New Roman"><FONT STYLE="text-decoration: underline">SIGNATURES</FONT></FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman">Dated:
      March       19, 2012<BR></FONT></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman">Nutra
Pharma Corp.</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman"><FONT STYLE="text-decoration: underline">/s/ Rik
Deitsch</FONT></FONT></DIV>
      <DIV STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman">By: Rik
Deitsch, Chief Executive Officer</FONT></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV STYLE="text-indent: 0pt"><BR></DIV>
      <DIV ID="PGBRK" STYLE="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">
        <DIV ID="FTR">
          <DIV ID="GLFTR" STYLE="width: 100%; text-align: left">&#160;</DIV>
        </DIV>
        <DIV ID="PN">
          <DIV STYLE="width: 100%; text-align: center">&#160;</DIV>
          <DIV STYLE="width: 100%; text-align: center">
            <HR NOSHADE SIZE="2" STYLE="color: black">
          </DIV>
        </DIV>
        <DIV ID="HDR">
          <DIV ID="GLHDR" STYLE="width: 100%; text-align: right">&#160;</DIV>
        </DIV>
      </DIV>
    </DIV>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v306433_8-k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 16362}]
{"company-data": {"conformed-name": "NUTRA PHARMA CORP", "cik": "0001119643", "assigned-sic": "2833", "irs-number": "912021600", "state-of-incorporation": "CA"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-32141", "film-number": "12700838"}, "business-address": {"street1": "2776 UNIVERSITY DRIVE", "city": "CORAL SPRINGS,", "state": "FL", "zip": "33065", "phone": "(954) 509-0911"}, "mail-address": {"street1": "2776 UNIVERSITY DRIVE", "city": "CORAL SPRINGS,", "state": "FL", "zip": "33065"}, "former-company": {"former-conformed-name": "CYBER VITAMIN COM", "date-changed": "20000717"}}
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): March 13, 2012
NUTRA
      PHARMA CORP.
(Exact
      name of registrant as specified in its
charter)
California
000-32141
91-2021600
(State
      or jurisdiction of
(Commission
(I.R.S.
      Employer
incorporation
      or organization)
File
      Number)
Identification
      No.)
2776
      University Drive
Coral
      Springs, Florida 33065
(Address
      of principal executive offices) (Zip
Code)
Registrant's
      telephone number: 954-509-0911
(Former
name or former address, if changed since last report)
Nutra
Pharma Corp. is referred to herein as "we", "our" or "us" or the "Company".
Item
1.01    Entry into a Material Definitive
Agreement.
On March 13,
2012, we signed a $10,000,000 maximum commitment amount Equity Purchase Agreement (the "Agreement") with Southridge
Partners, II. LP ("SPLP"), a Delaware Corporation.
The Agreement provides that we will sell to SPLP
(referred to in the Agreement as the "Investor") and SPLP will purchase up to ten million dollars
($10,000,000) of our common stock under specified terms in the Agreement. The Agreement provides that on any Put Date, we may
exercise a Put by the delivery of a Put Notice to SPLP. The number of Put Shares that SPLP will purchase will be determined
by dividing the investment amount specified in the Put Notice by the Purchase Price. The Investment amount identified in the
Put Notice will not be greater than the Maximum Put Amount, and, when taken together with any prior Put Notices, will not
exceed the Maximum Commitment of $10,000,000. On the Put Date, we will deliver to SPLP's brokerage account estimated
put shares equal to the investment amount indicated in the Put Notice divided by the closing price on the trading day
immediately proceeding the Put Date, multiplied by one hundred twenty five percent (125%). On the Trading Date immediately
following delivery of the Estimated Put Shares, SPLP will delivery payment by check or wire transfer to us an amount equal to
the part value of the Estimated Put Shares. In the event that, during a Valuation Period, the Closing Price on any Trading
Day falls more than twenty percent (20%) below the average of closing trade prices for the five (5) trading days immediately
preceding the date of our Put Notice, for each such Trading Day, the parties shall have no right and will be under no
obligation to purchase and sell one fifth (1/5) of the investment amount specified in the Put Notice, and the Investment
Amount will accordingly be deemed reduced by such amount. The Put Shares are contingent upon our filing of an S-1
Registration Statement with the Securities Exchange Commission and it becoming effective.
As a condition of executing the Agreement by SPLP, we
will issue to SPLP a promissory note in the amount of $50,000 upon the signing of the Agreement. The Note will be convertible
at SPLP's option into shares of our common stock at a conversion price equal to seventy percent (70%) of the average of
the two (2) lowest Closing Prices for the five (5) trading days immediately preceding a conversion notice. Additionally, we
agree to pay our own expenses in connection with preparation of the Agreement and performance of our obligations under the
Agreement, and we will pay a $25,000 fee to SPLP in cash or the issuance of an additional $25,000 in principal of the Note.
The Agreement is subject to various representations and warranties
by both parties to the Agreement.
Item
3.02    Unregistered Sales of Equity
Securities.
The
information contained above in Item 1.01 is hereby incorporated by
reference into this Item 3.02.
Item
9.01    Financial Statements and Exhibits.
(d)
Exhibits.
10.1
Equity Agreement, dated as of March 13, 2012, by and between the Company and
      Southridge Partners II, LP.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
      March       19, 2012
Nutra
Pharma Corp.
/s/ Rik
Deitsch
By: Rik
Deitsch, Chief Executive Officer